Skip to main content
. Author manuscript; available in PMC: 2022 Jul 23.
Published in final edited form as: Am J Transplant. 2020 Sep 15;21(3):978–992. doi: 10.1111/ajt.16266

Figure 4.

Figure 4

IL-33-Tregs do not demonstrate suppressive advantage in vitro. A, Schematic of in vitro suppression assay design. PBS- or IL-33-treated CBA/Ca splenocyte-derived CD4+CD25+ Tregs were cultured with CD4+CD25neg Teff responders stimulated with (B) H-2b allogeneic DC cells or (C) anti-CD3/anti-CD28 beads to assess their suppressive potency in vitro. B,C, Data are shown as means ± SD. Unpaired, independent groups (1:1, 1:2, 1:4, and 1:8) of 2 were analyzed using unpaired t tests (*P < .05; ns = not significant) [Color figure can be viewed at wileyonlinelibrary.com]